Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Orlando, Florida

This page shows live ClinicalTrials.gov search results for Orlando, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
6874
Shown on this page
12
Current sort
Recently updated
Location scope
Orlando, FL
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Orlando, Florida. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 757–768 of 6,874 matching trials in Orlando, FL.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Live official records

Open in full search
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)

NCT06741397
View directory record Official record
Conditions
HIV Infections
Interventions
CAB LA, New formulation of CAB LA
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
16 Years and older
Enrollment
229 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
25
States / cities
Birmingham, Alabama • Los Angeles, California • Palm Springs, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Nov 15, 2026, 3:13 AM EST
Recruiting Phase 3 Interventional

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

NCT07218926
View directory record Official record
Conditions
Gastrointestinal Neoplasms
Interventions
IDRX-42, Sunitinib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
49
States / cities
Phoenix, Arizona • Duarte, California • La Jolla, California + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Nov 15, 2026, 3:13 AM EST
Active, not recruiting Phase 3 Interventional

Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma

NCT00978458
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Neurotoxicity
Interventions
temozolomide, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy
Drug · Radiation
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
168
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 117 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Nov 15, 2026, 3:13 AM EST
Completed Not applicable Interventional

Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM

NCT04471844
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Optune®
Device
Lead sponsor
NovoCure Ltd.
Industry
Eligibility
18 Years and older
Enrollment
981 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
86
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Nov 15, 2026, 3:13 AM EST
Active, not recruiting Phase 3 Interventional

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

NCT03007147
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Calaspargase Pegol, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Dexrazoxane Hydrochloride, Doxorubicin, Etoposide, Filgrastim, Ifosfamide, Imatinib Mesylate, Laboratory Biomarker Analysis, Leucovorin Calcium, Levoleucovorin, Mercaptopurine, Methotrexate, Methylprednisolone, Pegaspargase, Prednisolone, Questionnaire Administration, Therapeutic Hydrocortisone, Thioguanine, Vincristine Sulfate
Procedure · Drug · Biological + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2034
U.S. locations
184
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 145 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Nov 15, 2026, 3:13 AM EST
Recruiting Phase 3 Interventional

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

NCT07684144
View directory record Official record
Conditions
Obesity, Overweight, Diabetes Mellitus, Type 2
Interventions
Maridebart Cafraglutide, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
950 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
31
States / cities
Gilbert, Arizona • Canoga Park, California • Cerritos, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Nov 15, 2026, 3:13 AM EST
Recruiting Phase 1Phase 2 Interventional

BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)

NCT07193511
View directory record Official record
Conditions
Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors, Urothelial Cancer
Interventions
AVZO-103, Combination Agent
Drug
Lead sponsor
Avenzo Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
15
States / cities
San Francisco, California • Aurora, Colorado • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Nov 15, 2026, 3:13 AM EST
Suspended Not applicable Interventional

A Study of Different Programs to Help ALL Patients With Taking Maintenance Medicine at Home

NCT06639958
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia
Interventions
Biospecimen Collection, Compliance Monitoring, Health Promotion and Education, Informational Intervention, Media Intervention, Medical Device Usage and Evaluation, Mercaptopurine, Questionnaire Administration, Telephone-Based Intervention, Training and Education
Procedure · Behavioral · Other + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
10 Years to 25 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
27
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Oakland, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Nov 15, 2026, 3:13 AM EST
Recruiting Phase 4 Interventional

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD

NCT04781140
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
100mg SPN-812, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
48 Months to 69 Months
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
54
States / cities
Saraland, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Nov 15, 2026, 3:13 AM EST
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Study of Sulthiame (S-054502) in Participants With Renal Impairment and Matched Healthy Controls

NCT07857837
View directory record Official record
Conditions
Renal Impairment
Interventions
Sulthiame
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Altamonte Springs, Florida • Miami Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Nov 15, 2026, 3:13 AM EST
Enrolling by invitation Phase 3 Interventional

A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)

NCT05352919
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
Litifilimab, Litifilimab-matching placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
864 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
38
States / cities
Phoenix, Arizona • Beverly Hills, California • Huntington Beach, California + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Nov 15, 2026, 3:13 AM EST
Recruiting Phase 3 Interventional

Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion Thrombectomy Trial

NCT05611242
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
MT+CAS with IV-AP, MT+CAS with PO-AP, MT+CAT with PO-AP
Procedure
Lead sponsor
Mercy Health Ohio
Other
Eligibility
18 Years to 79 Years
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
60
States / cities
Mobile, Alabama • Glendale, California • Irvine, California + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Nov 15, 2026, 3:13 AM EST